Why the study?
Does thymopoietin pentapeptide (TP5) suppress induced erythrocyte autoantibodies in C3H mice?
Does thymopoietin pentapeptide (TP5) suppress induced erythrocyte autoantibodies in C3H mice?
Thymopoietin pentapeptide (TP5) accelerates the loss of induced erythrocyte autoantibodies in mice, indicating potential immunomodulatory effects on autoimmunity.
Should not yet alter clinical autoimmunity management; leaves open TP5 translation from murine models.
C3H mice (young and old), when immunized with the cross-reacting rat erythrocytes, produced erythrocyte autoantibodies that usually persisted for more than 10 weeks. I.P. injection of thymopoietin pentapeptide (TP5) once or thrice weekly accelerated the loss of erythrocyte autoantibodies 7 weeks after immunization; 10 ng of TP5 was the optimal dose. The rat agglutinin responses of these immunized mice were unaffected by TP5 during the whole period of study. Spleen cells from rat erythrocyte-immunized mice, when transferred to syngeneic recipients undergoing similar immunization schedules, delayed the appearance of erythrocyte autoantibodies in the recipients. A greater delay was observed when spleen cells were taken from mice that had also received TP5 treatment.
No takes yet. Share an insight, caveat, or question.
Lau et al. (1980) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: